The Different Strategies for the Radiolabeling of [<sup>211</sup>At]-Astatinated Radiopharmaceuticals
Astatine-211 (<sup>211</sup>At) has emerged as a promising radionuclide for targeted alpha therapy of cancer by virtue of its favorable nuclear properties. However, the limited in vivo stability of <sup>211</sup>At-labeled radiopharmaceuticals remains a major challenge. This review provides a compre...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2024-05-01
|
| Col·lecció: | Pharmaceutics |
| Matèries: | |
| Accés en línia: | https://www.mdpi.com/1999-4923/16/6/738 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|